[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracic-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracic-diseases":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,69,98,125,157,181,203],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643363","evaluating-a-text-prompt-ai-assistant-for-chest-ct-scans-ai-report-study-100643363",false,"NCT07634861","Evaluating a Text-Prompt AI Assistant for Chest CT Scans (AI-REPORT Study)","An Evaluation Study of a Text-Based Chest CT-Assisted Diagnostic System: A Two-stage, Multicenter, Multireader Multicase (MRMC), Self-Crossover Controlled Trial","AI-REPORT","Inclusion Criteria:\n\n* Active board certification and ongoing routine clinical practice as an attending radiologist\n* Independent institutional authority for chest CT image interpretation and final official diagnostic report issuance\n* A minimum of three years of post-certification clinical experience in specialized thoracic imaging\n* Legal and cognitive competence for study participation, with voluntary provision of written informed consent after full understanding of study purpose, procedures, risks and benefits\n\nExclusion Criteria:\n\n* Direct participation in the development, training or validation of the trial's evaluated AI system\n* Ongoing participation in concurrent studies with potential risks of interpretation bias, cognitive fatigue or study procedure interference (investigator-assessed)\n* Any actual or perceived conflict of interest related to the evaluated AI system or its developers that may compromise objectivity in image interpretation and diagnostic reporting",true,"ALL","18 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to find out if an artificial intelligence (AI) system can help experienced radiologists write chest CT scan reports more quickly without lowering the quality of the report. Chest CT scans are common, and writing reports for them is a major part of a radiologist's job. In this trial, board-certified radiologists will interpret complex chest CT cases. For some cases, they will start with a complete draft report generated by the AI system, which they can review and edit as needed. For other cases, they will write the report from scratch without any AI help, following their usual routine. The main things we are measuring are: 1) how much time the AI draft saves, and 2) whether the final reports created with AI help are as good as or better than those written without it, as judged by other senior doctors who do not know which report came from which method. The hope is that this AI tool can make radiologists' work more efficient while maintaining high standards for patient care.",[28],"Thoracic Diseases","RECRUITING","2026-06-07",{"date":32,"type":33},"2026-06-09","ACTUAL",{"date":35,"type":22},"2026-06-20",{"date":37,"type":22},"2027-02-15",{"name":39,"class":40},"Shanghai Zhongshan Hospital","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100643559","ai-assisted-chest-ct-reporting-for-enhanced-speed-and-quality-the-double-ace-study-100643559","NCT07640906","AI-Assisted Chest-CT Reporting for Enhanced Speed and Quality (The DOUBLE-ACE Study)","A Multicenter Comparative Study Evaluating the Impact of an AI-Assisted Chest CT Reporting System on Real-world Radiologist Performance: The DOUBLE-ACE Study","DOUBLE-ACE","The study participants include both the radiologists whose performance is evaluated and the chest CT scans they interpret. Eligibility criteria are defined for both.\n\n1\\. Inclusion Criteria\n\n1.1 For Radiologists\n\n1. Board-certified radiologists specializing in or routinely performing thoracic imaging.\n2. Employed at one of the participating study centers for the entire duration of both the without-AI and with-AI study periods.\n3. Interpreted a minimum of eligible chest CT scans (e.g., \\> 50 scans) during both the without-AI and with-AI data collection periods.\n\n1.2 For Chest CT Scans\n\n1. Non-contrast chest CT examinations performed for any clinical indication.\n2. Scans completed and finalized during the defined with-AI or without-AI study periods.\n3. Patient age 18 years or older at the time of the scan.\n\n2\\. Exclusion Criteria\n\n2.1 For Radiologists:\n\n1. Radiologists who joined, left, or were on extended leave (e.g., \\>4 weeks) from the participating center between the with-AI and without-AI study periods.\n2. Radiologists who interpreted fewer than the minimum required number of eligible scans in either study period.\n3. Radiologists who voluntarily decline to have their de-identified performance data included in the study analysis.\n4. Radiologists who decline to provide demographic or occupational information (e.g., years of professional experience or sex)-variables that may serve as potential confounders-will be excluded from adjusted and stratified analyses that require such covariates.\n\n2.2 For Chest CT Scans\n\n1. CT scans of pediatric patients (age \\\u003C 18 years).\n2. Contrast-enhanced chest CT studies.\n3. Studies performed for specific procedural guidance (e.g., biopsy, ablation).\n4. Studies deemed technically inadequate for primary interpretation by radiologist (e.g., severe motion artifact, incomplete study).\n5. Studies for which the AI system fails to generate a valid preliminary report draft. This includes possible system failures, algorithm errors, or cases where the generated draft is deemed technically unusable (e.g., empty, garbled, or based on critically flawed image analysis).\n6. The lack of relevant information (diagnosis, clinical scenario, etc.). Chest CT data will be excluded from corresponding analyses if the required information, which is necessary for confounding control, subgroup analyses, or other pre-specified analyses, is unavailable. Such scenarios include data that cannot be retrospectively retrieved, incompletely recorded, or restricted due to ethical or institutional requirements.",{"count":51,"type":22},75,"OBSERVATIONAL","The goal of this observational study is to learn if an AI assistant tool can help doctors who read chest CT scans (called radiologists) write their reports faster and just as well or better. Chest CT scans are common pictures taken of the inside of the chest to help with diagnosis. The main questions the study aims to answer are: (1) Does using the AI tool save radiologists time when writing their reports? (2) Are the final reports written with the AI tool's help as good as or better than reports written without it? To answer these questions, researchers will compare two time periods at several hospitals. They will look at how long it took to write reports and how good the reports were, both from a time before the AI tool was available and from a time after it was in regular use. In this study, radiologists will use the AI tool as part of their normal daily work. The tool is built into the computer system they already use to look at scans. Researchers will then measure the time and quality of the reports produced during their regular shifts.",[28,55,56],"Chest CT Scan","Artificial Intelligence (AI) in Diagnosis",[58,59],"Chest CT scan","artificial intelligence","NOT_YET_RECRUITING","2026-06-05",{"date":63,"type":33},"2026-06-11",{"date":65,"type":22},"2026-06",{"date":67,"type":22},"2026-12",{"name":39,"class":40},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100635197","effect-of-manual-chest-wall-vibration-on-respiratory-function-and-chest-tube-duration-after-thoracic-surgery-100635197","NCT07549555","Effect of Manual Chest Wall Vibration on Respiratory Function and Chest Tube Duration After Thoracic Surgery","The Effect of Manual Chest Wall Vibration on Respiratory Functions and Chest Tube Duration in Patients Undergoing Thoracic Surgery","Inclusion Criteria:\n\n* Having undergone thoracic surgery\n* Having a chest tube in the postoperative period\n* Being hemodynamically stable\n* Agreeing to participate in the study\n* Being open to communication and cooperation\n\nExclusion Criteria:\n\n* Severe cardiac instability\n* Patients unable to tolerate the procedure due to neurological or cognitive impairment\n* Clinical conditions that would prevent the application of vibration to the chest wall\n* Patients diagnosed with pneumonia\n* Patients with a newly implanted transvenous or subcutaneous pacemaker",{"count":77,"type":22},60,[25],"This study was conducted to determine the effects of a manual vibration technique applied to the chest wall on the duration of chest tube placement, secretion clearance, and hemodynamic parameters in patients with chest tubes.",[28],[82,83,84,85,86,87],"Thoracic surgery","Chest tubes","Chest wall oscillation","Physical therapy modalities","Postoperative care","Airway Clearance Techniques","2026-04-16",{"date":90,"type":33},"2026-04-24",{"date":92,"type":33},"2025-10-01",{"date":94,"type":22},"2026-05",{"name":96,"class":40},"Saglik Bilimleri Universitesi",1,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":97},"100479346","phase-4-erector-spinae-block-for-thoracic-surgery-100479346","NCT05521789","Erector Spinae Block for Thoracic Surgery","Erector Spinae Blocks for Thoracic Surgery","Inclusion Criteria:\n\n* pulmonary resection\n* 18\\\u003Cage\\\u003C90\n\nExclusion Criteria:\n\n* pleurodesis\n* decortication\n* emergent surgery\n* local anesthetic allergy\n* intraoperative complication (inadvertent hemorrhage or conversion to open surgery)\n* bilateral pulmonary resection","90 Years",{"count":107,"type":22},70,[109],"PHASE4","The aim of this study is to determine if erector spinae injections with bolus infusions with local anesthetic decrease postsurgical pain and opioid consumption in patients undergoing pulmonary resection surgery.",[112,113,28,114,115],"Pulmonary Neoplasm","Pulmonary Cancer","Thoracic Cancer","Thoracic Neoplasms","2026-02-23",{"date":118,"type":33},"2026-02-25",{"date":120,"type":33},"2022-07-22",{"date":122,"type":22},"2027-07-21",{"name":124,"class":40},"George Washington University",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":18,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":97},"100595141","phase-4-effects-of-ciprofol-on-myocardial-injury-after-non-cardiac-surgery-in-video-assisted-thoracoscopic-surgery-100595141","NCT07028593","Effects of Ciprofol on Myocardial Injury After Non-cardiac Surgery in Video-Assisted Thoracoscopic Surgery","Effects of Ciprofol on Myocardial Injury After Non-cardiac Surgery (CP-MINS) in Patients Undergoing Video-Assisted Thoracoscopic Surgery: A Randomized, Double-Blind, Propofol-Controlled, Multicenter Trial","CP-MINS","Inclusion Criteria:\n\n1. Scheduled for elective video-assisted thoracoscopic (VATS)-assisted thoracic surgery (lobectomy, segmentectomy, wedge resection of two or more lung tissues, mediastinal tumor resection) under general anesthesia;\n2. Aged 45 to 80 years (inclusive) at the time of randomization;\n3. Expected postoperative hospital stay of ≥3 days;\n4. Signed a written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Patients allergic to propofol, Ciprofol, or analogs of drug excipient components (soybeans, eggs, milk);\n2. Patients with unstable angina;\n3. Patients with congestive heart failure or hemodynamic instability requiring vasopressor agents;\n4. Patients with severe COPD (FEV1 \\\u003C 1 L);\n5. Glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73m²;\n6. Patients with severe hepatic dysfunction (ALT or AST elevation exceeding 1.5 times the upper limit of normal);\n7. Male or female patients planning to conceive within the next 3 months;\n8. Pregnant or lactating female patients;","40 Years","80 Years",{"count":136,"type":22},1058,[109],"Myocardial injury after noncardiac surgery (MINS) refers to postoperative elevation of cardiac troponin (cTn) levels caused by underlying ischemic mechanisms (i.e., coronary artery supply-demand imbalance or atherosclerotic thrombosis) without obvious non-ischemic causes (such as pulmonary embolism), with at least one cTn concentration exceeding the 99th percentile of the test reference upper limit, regardless of whether clinical symptoms and ECG changes are present. MINS, including myocardial infarction and ischemic myocardial injury, typically occurs within 30 days after surgery, most commonly within the first 2 postoperative days. It is an independent risk factor for 30-day postoperative mortality and is also closely associated with increased risk of mortality and vascular complications within 2 years . MINS is a common cardiovascular complication after thoracic surgery. Therefore, reducing the incidence of MINS in non-cardiac thoracic surgery to improve patient outcomes is a critical issue in anesthetic management for thoracic surgery.\n\nCiprofol is a Class 1 innovative drug independently developed in China with global intellectual property rights. Currently, Ciprofol has completed Phase III clinical trials in China and the United States; its approved indications in China include sedation or anesthesia for various diagnostic procedures, general anesthesia for surgical operations, and sedation during intensive care unit (ICU) stays. Completed drug clinical trials and published clinical trial data of Ciprofol indicate that it can better maintain circulatory stability and ideal anesthetic depth during anesthesia induction and maintenance, making it a promising intravenous general anesthetic alternative to propofol.\n\nMaintaining hemodynamic stability is an important measure to reduce cardiovascular complications during the perioperative period. Given the good circulatory stability and sedative efficacy of Ciprofol, this study aims to investigate the impact of Ciprofol on MINS in non-cardiac thoracic surgery.",[140,28,141],"Myocardial Injury","Thoracoscopic Surgery",[143,144,145,146,147],"Myocardial Injury after non-cardiac surgery","Ciprofol","propofol","Video-Assisted Thoracoscopic Surgery","lung tumor","2026-01-26",{"date":150,"type":33},"2026-01-28",{"date":152,"type":33},"2025-07-31",{"date":154,"type":22},"2027-12",{"name":156,"class":40},"Tongji Hospital",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":163,"minAge":19,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":97},"100612180","effect-of-perioperative-high-dose-transdermal-nicotine-patch-on-pain-sensitivity-among-male-abstinent-tobacco-smokers-undergoing-thoracic-surgery-a-randomized-controlled-pilot-study-100612180","NCT07250230","Effect of Perioperative High-dose Transdermal Nicotine Patch on Pain Sensitivity Among Male Abstinent Tobacco Smokers Undergoing Thoracic Surgery: A Randomized Controlled Pilot Study","Inclusion Criteria:\n\n1. Male, aged 18-75 years, with a body mass index (BMI) of 18-28 kg\u002Fm2 Between;\n2. Thoracoscopic lobectomy\u002Fsegmental\u002Fwedge resection under general anesthesia;\n3. American Society of Anesthesiologists (ASA) classifications I-III Level;\n4. Regular smoking for more than 2 years, smoking more than 10 cigarettes per day in the past 6 months, and not successfully quitting smoking within 1 month (after admission, the doctor and nurse informed the smoking cessation plan to intervene before starting to stop smoking or 1 ≤ cigarette count ≤ 10 cigarettes\u002Fday in the past month), FTND score ≥ 2;\n5. No severe respiratory diseases, no serious cardiovascular and cerebrovascular diseases (hypertension is treated with SBP ≤ 160mmHg, DBP ≤ 90mmHg after systemic treatment);\n6. Obtain informed consent.\n\nExclusion Criteria:\n\n1. Those who have a history of alcoholism, long-term use of sedatives or analgesics;\n2. Patients with psychiatric and nervous system diseases (such as Parkinson's, depression, schizophrenia) and severe audio-visual dysfunction before surgery;\n3. Preoperative systolic blood pressure \\> 180mmHg or diastolic blood pressure \\> 110mmHg;\n4. Patients who were converted to thoracotomy during thoracoscopic surgery\n5. Patients who are transferred to the intensive care unit after surgery;\n6. Patients who refuse to use analgesic pump treatment\u002Fdo not configure the analgesic pump according to regulations;\n7. Patients who have self-removed patches\u002Fshort hospital stay resulting in a postoperative observation time of \\\u003C 48 hours","MALE","75 Years",{"count":166,"type":22},80,[25],"Globally, approximately 230 million adults undergo surgical procedures each year, with around 30% of patients maintaining smoking habits prior to surgery. Extensive clinical research has confirmed that tobacco exposure is a significant independent risk factor for perioperative complications. Epidemiological data indicate that long-term smokers experience a significantly higher all-cause mortality rate during hospitalization, approximately 20% greater than non-smokers, while the incidence of postoperative complications is 40% higher. Consequently, international guidelines universally recommend the establishment of standardized preoperative smoking cessation programs for surgical patients. Nicotine withdrawal, a typical clinical manifestation during smoking cessation, involves symptoms across multiple systems: neuropsychiatric symptoms such as mood depression, sleep disturbances, and irritability; autonomic dysfunction leading to postural dizziness and bradycardia; and metabolic dysregulation resulting in increased appetite and weight gain. Notably, these withdrawal symptoms exhibit a significant time-dependent pattern, typically peaking 24-72 hours after cessation. Multicenter studies have demonstrated that tobacco-dependent patients experience an average increase of IV Abstract 35-45% in opioid consumption within 24 hours postoperatively, with the duration of analgesic requirements extended by approximately 25%. However, some patients suffer from severe adverse reactions to opioids (e.g., nausea, vomiting, confusion), making the use of adjuvant medications for multimodal analgesia and optimized pain management particularly crucial. By the late 20th century, the analgesic properties of nicotine, a primary component of tobacco, were systematically studied and applied in clinical practice.",[170,28,171],"Nicotine Dependence","Analgesia","2026-01-20",{"date":174,"type":33},"2026-01-22",{"date":176,"type":33},"2025-11-30",{"date":178,"type":22},"2026-12-31",{"name":180,"class":40},"Henan Provincial People's Hospital",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":187,"targetDuration":189,"studyType":52,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":97},"100371613","thoracic-specimen-registry-100371613","NCT04118660","Thoracic Specimen Registry","Inclusion Criteria:\n\n* Subject must be \\> 18 years of age\n* Presumed or known or screening of Thoracic Diseases (which includes but not limited to the following: thoracic neoplasms (masses\u002Fnodules) malignant or benign, interstitial lung diseases (ILD), chronic obstructive pulmonary disease (COPD), thoracic infections, thoracic malignancies metastatic to other organs, other cancers metastatic to the thoracic cavity.",{"count":188,"type":22},7000,"50 Years","The purpose of the registry will be to support ongoing research in the etiology, early diagnosis, clinical management, and prognosis of lung cancer and other cancers and diseases of the thorax by developing a complete repository of specimens from patients with thoracic disease including but not limited to suspected lung cancer, mediastinal and pleural tumors, lung transplants and from patients at a very high risk of developing other thoracic cancers or other thoracic diseases.",[28,192,193],"Lung Cancer","Lung Transplant","2026-01-14",{"date":196,"type":33},"2026-01-16",{"date":198,"type":33},"2017-03-01",{"date":200,"type":22},"2028-01",{"name":202,"class":40},"Mayo Clinic",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":18,"minAge":210,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":213,"briefSummary":214,"conditions":215,"keywords":218,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":41},"100410898","geriatric-thoracic-surgery-ambulation-challenge-100410898","NCT04630496","Geriatric Thoracic Surgery Ambulation Challenge","Pre-Operative Exercise Challenge In Geriatric Thoracic Patients","Inclusion Criteria:\n\n* Patients Aged ≥ 65 years\n\n  * Who are preparing to undergo thoracic surgery at Brigham and Women's Hospital (BWH)\n\nExclusion Criteria:\n\n* Patients who are completely non-ambulatory (i.e. wheelchair-bound-patients) \\*\n* Those who lack capacity to consent due to cognitive disease.\n* Patient for which surgery is felt to be more urgent and therefore performed earlier then our required timeframe for intervention.\n* Patients with cardiac disease or angina for which formal cardiac testing is required for clearance.\n\n  * Our exclusion criteria do not include patients with gait disturbances or those who require assistance devices for ambulation.","65 Years",{"count":212,"type":22},30,[25],"This study is examining collecting data on steps walked (ambulation) per day by thoracic surgery patients over the age of 65 years-old before surgery.\n\nThe name(s) of the study device involved in this study is:\n\n* Fitbit inspire",[28,216,217],"Surgery","Therapy, Exercise",[28,219,220,221],"Lung Resection","Perioperative activity","Pedometer tracker","2025-04-09",{"date":224,"type":33},"2025-04-13",{"date":226,"type":33},"2021-08-25",{"date":228,"type":22},"2026-01-01",{"name":230,"class":40},"Dana-Farber Cancer Institute"]